Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program StudyZijun Y. Xu‐Monette, Ken H. Young, Santiago Montes‐Moreno et al.|Blood|2012Cited by 390
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program StudyCarlo Visco, Ken H. Young, Alexandar Tzankov et al.|Haematologica|2012Cited by 165
Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination TherapyMerry Y. Zhao, X. Frank Zhao|Clinical Cancer Research|2009Cited by 44